Dog Hemangiosarcoma Prognosis and Palliative Care

Hemangiosarcoma is an aggressive vascular cancer in dogs with poor prognosis, and palliative care can significantly improve quality of remaining life.

Key Facts

Hemangiosarcoma (HSA) is a malignant tumor of blood vessel cells, most common in German Shepherds and Golden Retrievers
Splenic HSA is most common; cardiac and dermal forms also occur
Splenic HSA often presents acutely with internal bleeding requiring emergency splenectomy
Without treatment, median survival after splenic HSA rupture is less than 1-2 weeks
With splenectomy plus chemotherapy (doxorubicin-based), median survival extends to 4-6 months
Immunotherapy and Chinese herbal supplements (yunnan baiyao) are used adjunctively with mixed evidence
Quality of life between bleeds is often excellent, making palliative management viable for many owners

Welfare Considerations

HSA causes sudden, severe internal hemorrhage that is acutely distressing. Even after splenectomy, the risk of re-bleeding from metastatic sites persists. Palliative care focuses on monitoring, pain management, and maximizing good days between crises. Clear communication with owners about signs of rebleeding allows timely end-of-life decisions.

What You Can Do

Discuss prognosis honestly with your vet before pursuing surgery and chemotherapy
Establish a quality-of-life scale to guide end-of-life decision making
Monitor for signs of rebleeding including rapid deterioration, pale gums, and weakness
Explore palliative-only approaches for dogs not good surgical candidates
Connect with HSA-specific support communities for guidance from other dog owners